Veradermics, Incorporated, a clinical-stage biopharmaceutical company, has been making significant strides in the health care sector, particularly in the realm of dermatologic and aesthetic conditions. Headquartered in New Haven, Connecticut, and listed on the New York Stock Exchange, Veradermics has been a focal point for investors and healthcare professionals alike, given its innovative approach to treating a range of dermatological issues.
As of June 22, 2026, Veradermics’ stock closed at $103.6, reflecting a robust market presence despite a challenging year marked by a 52-week high of $117.71 on May 5, 2026, and a low of $32 on February 3, 2026. The company’s market capitalization stands at approximately $4.33 billion, underscoring its substantial impact within the biopharmaceutical landscape.
Veradermics’ primary focus is on developing novel therapeutics for dermatologic and aesthetic conditions, with a particular emphasis on pattern hair loss (PHL) affecting both adults and children. The company’s flagship product, VDPHL01, is an oral, non-hormonal treatment designed for chronic hair loss therapy in men and women. This innovative approach has positioned Veradermics as a leader in the treatment of androgenetic alopecia, a condition that affects millions worldwide.
In addition to VDPHL01, Veradermics is advancing its portfolio with several other promising treatments. VDMN, a dissolvable microarray patch technology, is being developed for the immunotherapy of common warts. This technology represents a significant advancement in non-invasive treatment options for patients. VDAA, another key product in development, targets alopecia areata, offering hope to those affected by this unpredictable and often distressing condition. Furthermore, VDMC is being developed for the treatment of molluscum contagiosum, a viral infection that causes raised, pearl-like papules or nodules on the skin.
Veradermics’ commitment to innovation extends to atopic dermatitis, a chronic skin condition characterized by itchy, inflamed skin. The company’s research and development efforts are geared towards providing effective and accessible treatments for this condition, which affects a significant portion of the pediatric and adult populations.
The company’s strategic focus on both adult and pediatric populations, along with its engagement with healthcare providers, clinicians, and the broader medical and clinical research community, underscores its comprehensive approach to addressing dermatologic and aesthetic conditions. Since its incorporation in 2019, Veradermics has demonstrated a clear vision and dedication to improving patient outcomes through cutting-edge research and development.
Despite a negative price-to-earnings ratio of -6.37, indicative of the company’s current financial performance challenges, Veradermics’ long-term prospects remain promising. The company’s innovative pipeline and commitment to addressing unmet medical needs in dermatology position it as a key player in the health care sector. As Veradermics continues to advance its therapeutic offerings, it is poised to make significant contributions to the field of dermatology, ultimately enhancing the quality of life for patients worldwide.
